These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
501 related items for PubMed ID: 18227473
1. Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Massi-Benedetti M, Orsini-Federici M. Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473 [Abstract] [Full Text] [Related]
2. Protection of pancreatic beta-cells: is it feasible? Bonora E. Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375 [Abstract] [Full Text] [Related]
3. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Campbell RK. J Am Pharm Assoc (2003); 2009 Jan; 49 Suppl 1():S10-5. PubMed ID: 19801360 [Abstract] [Full Text] [Related]
6. [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain]. Hermann LS, Melander A. Lakartidningen; 1999 Dec 15; 96(50):5616-9. PubMed ID: 10643226 [Abstract] [Full Text] [Related]
7. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. Bermúdez V, Cano R, Cano C, Bermúdez F, Leal E, Acosta K, Mengual E, Arraiz N, Briceño C, Gómez J, Bustamante M, Aparicio D, Cabrera M, Valdelamar L, Rodriguez M, Manuel V, Hernández R. Am J Ther; 2008 Dec 15; 15(4):409-16. PubMed ID: 18645347 [Abstract] [Full Text] [Related]
8. beta-cell function and anti-diabetic pharmacotherapy. Del Prato S, Bianchi C, Marchetti P. Diabetes Metab Res Rev; 2007 Oct 15; 23(7):518-27. PubMed ID: 17883249 [Abstract] [Full Text] [Related]
9. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Raskin P. Diabetes Metab Res Rev; 2008 Oct 15; 24(1):3-13. PubMed ID: 17968971 [Abstract] [Full Text] [Related]
11. Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth. Holloway AC, Hettinga BP, Gerstein HC. J Diabetes; 2011 Mar 15; 3(1):74-81. PubMed ID: 21040499 [Abstract] [Full Text] [Related]
12. Redefining insulin therapy in type 2 diabetes mellitus. Rosenstock J. Postgrad Med; 2004 Nov 15; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676 [Abstract] [Full Text] [Related]
13. The importance of beta-cell management in type 2 diabetes. Standl E. Int J Clin Pract Suppl; 2007 Jun 15; (153):10-9. PubMed ID: 17594389 [Abstract] [Full Text] [Related]
15. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Sheffield CA, Kane MP, Busch RS. Pharmacotherapy; 2007 Oct 15; 27(10):1449-55. PubMed ID: 17896900 [Abstract] [Full Text] [Related]
17. Pharmacotherapies for diabetes management: an update for the practicing clinician. Meneghini L, Hirsch IB. Semin Thorac Cardiovasc Surg; 2006 Oct 15; 18(4):379-89. PubMed ID: 17395035 [Abstract] [Full Text] [Related]
18. Initiating insulin in patients with type 2 diabetes. Aoki TJ, White RD. J Fam Pract; 2007 Aug 15; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139 [Abstract] [Full Text] [Related]
19. [Development of body weight during antidiabetic treatment]. Hamann A. Dtsch Med Wochenschr; 2006 Dec 15; 131 Suppl 8():S255-8. PubMed ID: 17139582 [Abstract] [Full Text] [Related]